RA0381

antibody from Oursmab

Targeting: IL31RA CRL, CRL3, GLM-R, Glmr, IL-31RA

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0381

Provider

Oursmab

Product name

Nemolizumab (Biosimilar Reference Antibody) (IL31RA)

Antibody type

Monoclonal

Description

Nemolizumab is a humanized monoclonal antibody that targets the interleukin-31 receptor A (IL-31RA), a key component of the receptor for interleukin-31 (IL-31). By binding to IL-31RA, it blocks the interaction between IL-31 and its receptor, thereby inhibiting downstream JAK/STAT signaling that drives pruritus (itch) and inflammation. IL-31 is a major pruritogenic cytokine in atopic dermatitis (eczema). Nemolizumab is approved in Japan for the treatment of pruritus associated with atopic dermatitis and is under regulatory review in other regions for the same indication. It is administered via subcutaneous injection and has shown significant efficacy in reducing itch and improving skin lesions.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.